Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1985-04-09
1987-07-14
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536121, A61K 3170, C07H 2300
Patent
active
046802860
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to a method of negating the toxic effects of gold compounds. More particularly, the present invention relates to a method of negating the toxic effects of gold compounds used in the treatment of rheumatoid arthritis, which method comprises administering to a patient a selenium-containing compound. The present invention is also concerned with a novel selenium-containing gold compound which can be effectively used as a so-called gold compound type anti-rheumatoid arthritis medicine which can self-detoxify gold toxicity.
The most common form of chronic inflammatory arthritis is rheumatoid arthritis, which is characterized by symmetrical inflammatory polyarthritis, morning stiffness and positive rheumatoid factor. Over more than 100 diseases have been classified as arthritis, in addition to chronic inflammatory arthritis.
Each decision to treat with a drug requires careful therapeutic weighing of the hazards and the benefits of the drug versus the disability caused by the symptoms. Various groups of drugs useful for arthritis include salicylates, indole derivatives, propionic acid derivatives, phenylbutazone and oxyphenbutazone, penicillamine, corticosteroids, cytotoxic drugs and anti-gout agents. For an excellent review on these anti-arthritic drugs, a review article written by J. A. Markenson, appearing in Drug Therapy, January, 1981, page 45 dives a comparative overview of these types of classes of drugs. As mentioned above, there are various drugs effective in the treatment of arthritis, however, gold compounds used in gold therapy are most effective as anti-rheumatoid agents, and the gold therapy should be considered in patients with active disease who fail to respond to the plethora of drugs previously mentioned to reduce inflammation.
Active adult and juvenile rheumatoid arthritis are the principal indications where administration of these agents are used, but beneficial effects have also been obtained in some patients with psoriatic arthritis. Although their exact mechanism of action is unknown, the gold compounds exert an anti-inflammatory effect in these disorders, and unlike other anti-arthritic drugs may affect the course of the disease.
There are essentially four kinds of gold compound type anti-rheumatoid agents in the marketplace which are used in gold therapy. One of the first anti-rheumatic compounds was gold sodium thiomalate. Preparation of this compound can be found in U.S. Pat. No. 1,994,213. Other gold containing drugs are 1-thio-D-glucopyranosato gold and [[(phenylcarbamoyl)methyl]-thio] gold. Preparation of the latter compound can be found in U.S. Pat. No. 2,451,841. The fourth drug is known chemically as (2,3,4,6-tetra-O-acetyl-1-thio-.beta.-D-glucopyranosato-S-triethylphosphin e) gold. U.S. Pat. Nos. 3,635,945 and 3,708,579 describe the preparation and use of this drug. These four gold compounds offer various degrees of relief in rheumatoid arthritis.
The gold therapy using the gold compounds as described above is effective in the treatment of rheumatoid arthritis, but is accompanied by side effects. Therefore, the gold compounds should be used with extreme cautions. In order to be effective, high doses of gold compounds are required. General method of administering to a patent gold compounds in the treatment of rheumatoid arthritis is described below.
In adults the initial single weekly injections of 10 mg are given the first week, 25 mg the second week, 25 or 50 mg the third week and 50 mg each week thereafter until a total dosage of 800 mg to 1 g has been administered. If there is no response after 1 g has been given, the drug should be discontinued. If the patient has improved and no toxic effects have been developed, dosage can be reduced to 50 mg every two weeks for 4 doses, every three weeks for 4 doses, and then monthly. A remission after one year of maintenance therapy has been considered as an indication for complete withdrawal of the drug, but many physicians now feel that gold therapy probably can continue indefinitely, on a reduced dosage sch
REFERENCES:
patent: 4096250 (1978-06-01), Hill
Dumas Phillip E.
Stockel Richard F.
LandOfFree
Use of selenium-containing compounds for negating the toxic effe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of selenium-containing compounds for negating the toxic effe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of selenium-containing compounds for negating the toxic effe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1427599